P1.09-31 Clinicopathological Features and Genomic Profiling of Pulmonary Blastoma with High-Grade Fetal Adenocarcinoma Component
J. Zhao,C. Xiang,P. Wang,P. Guo,J. Zheng,H. Han-Zhang,K. Yu,R. Zhao,J. Zhang,Y. Han
DOI: https://doi.org/10.1016/j.jtho.2019.08.1060
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:Pulmonary blastoma (PB) is a very rare subtype of sarcomatoid carcinoma with typically low-grade fetal lung adenocarcinoma (L-FLAC) and primitive mesenchymal components. Very few cases of PB contain the high-grade fetal lung adenocarcinoma (H-FLAC) component. The present study was designed to investigate the clinicopathological characteristics and the genomic heterogeneity of epithelial and mesenchymal in PB with H-FLAC. Three surgically resected PB cases with H-FLAC component were enrolled in the study. The epithelial of the first case consisted of mostly H-FLAC mixed with limited amount of L-FLAC. The other two PB tumors contained pure H-FLAC and mesenchymal components. Clinic-pathologic information and prognostic data were retrospectively reviewed. Diagnostic immunohistochemistry was performed. The epithelial and mesenchymal components were macroscopically dissected to profile the genetic alterations separately using capture-based targeted sequencing. A commercialized panel, consisting of 520 cancer-related genes, was used. The cells of H-FLAC components in PB showed obvious atypia with more necrosis and enteric adenocarcinoma-like morphology. The squamoid morules were absent in H-FLAC. Proliferation index of the H-FLAC components (30%-80%) was higher than that of the mesenchymal (15%-20%). No aberrant nuclear expression of β-catenin protein and missense mutation in exon 3 of CTNNB1 gene were observed in H-FLAC and all mesenchymal cells. Within a tumor, epithelial and mesenchymal components exhibited relatively comparable molecular profile. In patient 1, 4 mutations: PB1, FAT3, PTCH1 and LRP1B were shared by both epithelial and mesenchymal components. Epithelial component had additional mutations in BCOR, CTNNB1, CTCF, FAT1 and DICER1. In patient 2, 12 mutations were shared. The epithelial component had BRCA2 mutations and the mesenchymal component had mutations in CREBBP, ALK, DNMT3A, ASXL2, MYCN and RICTOR. Patient 3 had 6 shared mutations. The epithelial component had an additional mutation in KAT6A and the mesenchymal had an additional mutation in APC. Furthermore, both epithelial and mesenchymal components showed significant interpersonal heterogeneity. In other words, the mutation spectrum of the same component (epithelial or mesenchymal) varies significantly among patients. Surprisingly, not a single common mutation was found in the same component among the 3 patients. Collectively, we observed heterogeneity between epithelial and mesenchymal components of the same tumor. In addition, we also observed significant inter-personal heterogeneity of the same component among different patients. Parallel detection of genetic abnormalities in epithelial and mesenchymal could provide further evidence to clarify the histopathological difference and molecular heterogeneity in pulmonary blastoma.